
Analyzing the ClinicalTrials.gov database, researchers found that after trial registration became a requirement for publication in major scientific journals in 2005, the number of newly registered trials rose from 9,321 in 2006 to 18,400 in 2014.
NIH-funded trials dipped slightly from 1,376 in 2006 to 1,048 in 2014, while industry trials increased from 4,585 to 6,550.
Adjusted for inflation, the NIH budget fell by 14 percent over this period, which may explain some of the decrease, according to the authors of the research letter in JAMA.
The pharmaceutical industry tests its own products, while the NIH funds tests of treatment approaches, including lifestyle interventions or drug comparisons, which industry tends not to fund because they do not lead to an increase in their bottom line, said coauthor Dr. Stephan Ehrhardt of Johns Hopkins Bloomberg School of Public Health in Baltimore.












Comment: Insuring a consistent revenue stream is the primary focus of the pharmaceutical industry. Thus, when data from clinical trials is not favorable to the industry, it is either suppressed or manipulated to show positive results. Studies have shown that industry funded trials are much more likely to show favorable outcomes than government funded studies.